Articles related to Urology

The management of low-risk prostate cancer has seen a significant shift over the last two decades, with active surveillance increasingly becoming the preferred approach. However, despite this progress, the overtreatment of low-risk disease remains a concern, underscoring the need for continued refinement in patient selection and monitoring strategies.

A recent phase 3 trial has shown that the combination of nivolumab and gemcitabine–cisplatin significantly improves survival rates in patients with previously untreated advanced urothelial carcinoma. This combination therapy resulted in a median survival of 21.7 months compared to 18.9 months with gemcitabine–cisplatin alone.

A recent study from Fox Chase Cancer Center has revealed that as many as 23% of cystic renal masses may carry high-grade, or aggressive, disease. This finding challenges the prevailing assumption of their low-risk nature and underscores the need for more discerning diagnostic and treatment strategies.

As healthcare professionals, it’s crucial to understand that PDE5 inhibitors, commonly prescribed for erectile dysfunction and pulmonary arterial hypertension, have been linked to retinal and vision changes. This highlights the importance of monitoring patients on these medications closely.

According to investigators, definitive local therapy for patients with cT4 prostate cancer may improve local control and survival outcomes.

The phase 3 trial showed that enzalutamide, when used as a monotherapy or in combination with leuprolide, resulted in superior metastasis-free survival rates for patients with high-risk biochemical recurrence of prostate cancer.